OPKO Health Announces Q1 2025 Financial Results Release and Conference Call
PorAinvest
jueves, 17 de abril de 2025, 10:49 am ET1 min de lectura
OPK--
Investors and analysts are encouraged to pre-register for the call to gain immediate access. The conference call details are as follows: U.S. callers can dial 833-630-0584, while international participants can dial 412-317-1815. A webcast of the call will be available at OPKO's Investor Relations page and on the company's website. A telephone replay will be available until May 7, 2025, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 3746692. A webcast replay will be available approximately one hour after the completion of the live conference call.
OPKO Health focuses on establishing industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and proprietary technologies. The company is headquartered in Miami and has a strong presence in various therapeutic areas, including Oncology, Rare Disease, and Neuroscience.
For more information about OPKO Health, visit [www.opko.com](http://www.opko.com). Investor inquiries can be directed to Alliance Advisors IR at 310-691-7100 or via email at ybriggs@allianceadvisors.com or bvoss@allianceadvisors.com.
References:
[1] https://www.morningstar.com/news/globe-newswire/9423773/opko-health-to-report-first-quarter-2025-financial-results-on-april-30-2025
[2] https://www.ipsen.com/general/q1-2025-sales-update/
TOI--
OPKO Health Inc. will release its Q1 2025 financial results on April 30, 2025, and host a conference call to discuss the results and provide financial guidance. Investors can pre-register for the call for immediate access. The company is focused on rapidly growing markets through its biopharmaceutical and diagnostics expertise.
OPKO Health Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, has announced that it will release its first-quarter 2025 financial results on April 30, 2025. The company will provide an update on its operating and financial performance during a conference call and live audio webcast scheduled to begin at 4:30 p.m. Eastern time.Investors and analysts are encouraged to pre-register for the call to gain immediate access. The conference call details are as follows: U.S. callers can dial 833-630-0584, while international participants can dial 412-317-1815. A webcast of the call will be available at OPKO's Investor Relations page and on the company's website. A telephone replay will be available until May 7, 2025, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 3746692. A webcast replay will be available approximately one hour after the completion of the live conference call.
OPKO Health focuses on establishing industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and proprietary technologies. The company is headquartered in Miami and has a strong presence in various therapeutic areas, including Oncology, Rare Disease, and Neuroscience.
For more information about OPKO Health, visit [www.opko.com](http://www.opko.com). Investor inquiries can be directed to Alliance Advisors IR at 310-691-7100 or via email at ybriggs@allianceadvisors.com or bvoss@allianceadvisors.com.
References:
[1] https://www.morningstar.com/news/globe-newswire/9423773/opko-health-to-report-first-quarter-2025-financial-results-on-april-30-2025
[2] https://www.ipsen.com/general/q1-2025-sales-update/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios